| Oct 28 |
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
|
| Oct 23 |
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
|
| Aug 28 |
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
|
| Aug 24 |
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
|
| Aug 19 |
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
|
| Aug 9 |
Monte Rosa Therapeutics GAAP EPS of -$0.43, revenue of $4.7M
|
| Aug 8 |
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 8 |
Monte Rosa Therapeutics: Q2 Earnings Snapshot
|
| Aug 8 |
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Jul 8 |
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
|
